ESMO review: advances in immunotherapy, EMA dialogue and patient power
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise